- Tags: AMD
Pipeline
Eyconis initiates first-in-human wet AMD trial on anti-VEGF therapy
EYC-0305 is under evaluation as a potential long-acting treatment designed for 6-month or longer dosing intervals via IVT injection.
Pipeline
EyePoint’s DURAVYU delivers mixed endpoint results in first phase 3 wet AMD trial
Primary endpoint not achieved in full dataset while ad-hoc analysis excluding asymmetric cohort demonstrated non-inferiority to on-label aflibercept.
Research
Eyedaptic AI smart glasses deliver 5.7-line acuity gain in AMD
Study demonstrates significant and immediate VA improvements in patients with advanced retinal disease.
Research
NSAID use may lower AMD risk
Prescribed patients appear less likely for disease development, with the association observed across multiple AMD subtypes and several commonly used medications
Pipeline
4DMT reports new phase 2b gene therapy data for wet AMD
New 2-year data demonstrates an overall 78% treatment reduction in patients treated with 4D-150 compared to bimonthly 2 mg aflibercept.
Products
Biocon launches Eylea biosimilar to US market
With commercial rights acquired from Santen, YESAFILI (aflibercept-jbvf) is indicated for the treatment of AMD, DME, DR, and macular edema following RVO.
Research
Adverum reports 5-year extension data on wet AMD gene therapy
At ASRS 2026, the OPTIC extension finds a single Ixo-vec injection led to a 87% cumulative reduction in annualized anti-VEGF injections.
Products
FDA approves Outlook's LYTENAVA for wet AMD
The VEGF inhibitor is now the first and only on-label ophthalmic formulation of bevacizumab for wet AMD treatment.
Research
Mediterranean diet linked to slower AMD progression
Diet aherence associated with slower AMD progression at every disease stage, with specific food components mattering most depending on the stage.
Research
New SYFOVRE data extend GA benefit to patients with concurrent wet AMD
SYFOVRE demonstrates reduced photoreceptor and RPE loss in GA patients and those with concomitant nAMD.
Pipeline
Oculgen enrolls first US patient in global phase 2/3 wet AMD trial
Company aims to utilize 36-week data from the STAT trial to support a BLA following its recent IND approval.
Pipeline
Ollin raises $330M to advance OLN324 in phase 3 studies for DME and wet AMD
Financing to support global clinical development of its bispecific antibody programs following promising phase 1b data readout in a head-to-head against faricimab.
Products
Harrow relaunches biosimilar Byooviz in the US
With commercial rights acquired from Samsung Bioepis, the FDA-approved interchangeable therapy to Lucentis is indicated for the treatment of wet AMD, RVO, and mCNV.
Pipeline
FDA accepts Outlook's fourth wet AMD BLA submission
The latest BLA package of ONS-5010 / LYTENAVA (bevacizumab-vikg) has received a PDUFA target action date for late July.
Products
FDA approves Lupin's Lucentis biosimilar injection
Ranluspec (ranibizumab-hkdz) marks the third ranibizumab biosimilar cleared in the U.S. to treat five retinal indications.
Pipeline
Outlook resubmits wet AMD BLA for bevacizumab after FDA appeal win
Marks fourth attempt to secure approval for the potential first on-label bevacizumab product specifically formulated for IVT retinal use in the US.
Pipeline
Outlook Therapeutics wins FDA appeal for wet AMD BLA
Decision follows company’s challenge to its third rejected package of ONS-5010 / LYTENAVA (bevacizumab-vikg); fourth submission expected in June.
Research
Neuvasq highlights novel antibody approach for restoring blood-retina barrier in wet AMD and DME
Preclinical data of NVQ401 and NVQ501 demonstrate improvements in BRB integrity and function in vascular retinopathy models.
Pipeline
Lineage reports positive 36-month findings on GA cell therapy
Results from the phase 1/2a trial of OpRegen demonstrate sustained BCVA and structural improvements.
Research